Pharming Group N.V. (PHAR) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pharming Group N.V. (PHAR) Healthcare & Pipeline Overview

Pharming Group N.V. develops and commercializes protein replacement therapies and precision medicines, primarily focusing on rare diseases with unmet medical needs. Their lead product, Ruconest, targets acute hereditary angioedema, positioning them in the niche biotechnology market with a focus on specialized treatments.

What Is the Investment Thesis for PHAR?

Pharming Group N.V. presents a focused investment opportunity within the rare disease biopharmaceutical space. With a P/E ratio of 521.4 and a profit margin of 3.4%, the company demonstrates profitability, albeit with room for expansion. Key value drivers include the continued commercial success of Ruconest and the advancement of its pipeline products, such as leniolisib for APDS. Upcoming catalysts include potential regulatory approvals and clinical trial results for its developmental therapies. The company's collaborations with Novartis and Orchard Therapeutics also provide avenues for growth and diversification. Potential risks include competition from other HAE treatments and the inherent uncertainties associated with drug development and regulatory approval processes. The company's beta of 0.12 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

PHAR Key Highlights

Market capitalization of $827M reflects investor valuation of Pharming's current and future potential.

• Gross margin of 88.1% indicates strong pricing power and efficient production of Ruconest.
• Profit margin of 3.4% demonstrates profitability, with opportunities for improvement through operational efficiencies and pipeline expansion.
• The company's lead product, Ruconest, addresses a critical need in the treatment of acute hereditary angioedema (HAE).
• Strategic collaborations with Novartis and Orchard Therapeutics plc enhance research and development capabilities.

Who Are PHAR's Competitors?

PHAR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PHAR's Key Strengths?

Lead product Ruconest addresses a critical need in HAE treatment.

• Strong gross margin of 88.1% indicates efficient operations.
• Pipeline of potential therapies for other rare diseases.
• Strategic collaborations with Novartis and Orchard Therapeutics.

What Are PHAR's Weaknesses?

Relatively small profit margin of 3.4%.

• Reliance on Ruconest for the majority of revenue.
• Limited geographic presence compared to larger pharmaceutical companies.
• High P/E ratio of 521.4 may indicate overvaluation.

What Could Drive PHAR Stock Higher?

Clinical trial results for leniolisib in activated PI3K delta syndrome (APDS).

• Regulatory approvals for rhC1INH in pre-eclampsia, acute kidney injury, and COVID-19.
• Expansion of Ruconest's market share in existing and new markets.
• Strategic collaborations to expand product portfolio and geographic reach.

What Are the Key Risks for PHAR?

Rich valuation — a P/E of 521.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Competition from other HAE treatments.
• Regulatory hurdles and delays in drug approval processes.
• Patent expiration and generic competition.
• Economic downturns and healthcare cost containment measures.
• Currency fluctuations affecting the value of the ADR.

What Are the Growth Opportunities for PHAR?

• Expansion of Ruconest's Market Share: Pharming can further penetrate the hereditary angioedema (HAE) market by increasing awareness among patients and healthcare providers, improving diagnostic rates, and expanding its geographic reach. The global HAE market is projected to grow, driven by the need for effective treatments for acute attacks. Pharming's focus on recombinant human C1 esterase inhibitor therapy positions it to capture a larger share of this market.
• Development and Commercialization of Leniolisib: Leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, represents a significant growth opportunity for Pharming. Targeting activated PI3K delta syndrome (APDS), a rare immunodeficiency disorder, leniolisib has the potential to address a critical unmet need. Successful clinical trials and regulatory approvals could lead to substantial revenue generation and establish Pharming as a leader in the treatment of APDS.
• Advancement of rhC1INH Pipeline: Pharming's development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19 offers multiple avenues for growth. These indications represent significant market opportunities, and positive clinical trial results could lead to regulatory approvals and commercialization. The potential to address these conditions with rhC1INH could diversify Pharming's product portfolio and revenue streams.
• Strategic Collaborations and Acquisitions: Pharming can pursue strategic collaborations and acquisitions to expand its pipeline, access new technologies, and enter new therapeutic areas. Partnering with other biotechnology companies or acquiring promising assets could accelerate Pharming's growth and enhance its competitive position. These collaborations could provide access to novel drug candidates and expand Pharming's expertise in rare diseases.
• Geographic Expansion: Pharming can expand its commercial operations into new geographic markets to increase its revenue and global presence. Entering emerging markets with unmet medical needs for rare diseases could provide significant growth opportunities. Establishing partnerships with local distributors and regulatory experts can facilitate market entry and ensure compliance with local regulations.

What Are PHAR's Competitive Advantages?

• Patent protection for Ruconest and other pipeline products.
• Orphan drug designation provides market exclusivity for certain indications.
• Specialized expertise in protein replacement therapies and precision medicines.
• Established relationships with key opinion leaders and patient advocacy groups.
• Strategic collaborations with Novartis and Orchard Therapeutics.

What Does PHAR Do?

Pharming Group N.V. is a biopharmaceutical company dedicated to developing and commercializing innovative protein replacement therapies and precision medicines for rare diseases and unmet medical needs. Founded with the vision of addressing critical gaps in treatment options for patients with rare conditions, the company has evolved into a key player in the biotechnology sector. Pharming's lead product, Ruconest, a recombinant human C1 esterase inhibitor, is used for the treatment of acute hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder. Beyond Ruconest, Pharming is actively engaged in the development of several other promising therapies, including rhC1INH for pre-eclampsia, acute kidney injury, and COVID-19, leniolisib for activated PI3K delta syndrome (APDS), and alpha-glucosidase therapy for Pompe and Fabry diseases. The company has established strategic collaborations with Novartis and Orchard Therapeutics plc to expand its research, development, and commercialization capabilities. Headquartered in Leiden, the Netherlands, Pharming Group N.V. operates in the United States, Europe, and internationally, striving to improve the lives of patients with rare diseases through innovative and accessible therapies.

What Products and Services Does PHAR Offer?

• Develops and commercializes protein replacement therapies.
• Focuses on precision medicines for rare diseases.
• Offers Ruconest for the treatment of acute hereditary angioedema (HAE).
• Develops rhC1INH for pre-eclampsia, acute kidney injury, and COVID-19.
• Develops leniolisib for activated PI3K delta syndrome (APDS).
• Engages in alpha-glucosidase therapy for Pompe and Fabry diseases.
• Collaborates with Novartis on drug development.
• Partners with Orchard Therapeutics on gene therapy for HAE.

How Does PHAR Make Money?

• Develops and patents novel therapies for rare diseases.
• Commercializes its products through direct sales and distribution networks.
• Generates revenue from the sale of Ruconest and potential future products.
• Collaborates with other companies for research, development, and commercialization.
• Focuses on orphan drug designations to secure market exclusivity.

What Industry Does PHAR Operate In?

Pharming Group N.V. operates within the biotechnology industry, specifically targeting the rare disease market. This segment is characterized by high unmet medical needs and often benefits from regulatory incentives such as orphan drug designation. The competitive landscape includes companies developing therapies for hereditary angioedema and other rare genetic disorders. The global rare disease market is projected to reach significant growth in the coming years, driven by increased awareness, improved diagnostics, and advancements in personalized medicine. Pharming's focus on protein replacement therapies and precision medicines positions it to capitalize on these trends.

Who Are PHAR's Key Customers?

• Patients with rare diseases, particularly hereditary angioedema (HAE).
• Hospitals and clinics that treat patients with rare diseases.
• Specialty pharmacies that dispense medications for rare diseases.
• Healthcare providers who prescribe Pharming's products.
• Research institutions and collaborators.

Wall Street analysts project Pharming Group N.V. revenue of about $390.6M for fiscal 2026, with EPS near $0.23.

Quarterly Financial Performance: Pharming Group N.V.

Revenue for Pharming Group N.V. came in at $90.2M during Q2 2026, a 24.5% improvement versus the preceding quarter. The company recorded net income of $1.6M, with diluted EPS of $0.02. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, PHAR averaged $0.03 in diluted EPS.

PHAR Valuation & Market Position

With a $827M market cap, Pharming Group N.V. sits in the small-cap segment of the market. Relative to its peer group, PHAR's quantitative score of 53/100 is below the peer average of 81/100.

Return on equity for Pharming Group N.V. stands at 4.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.5%, showing how much profit it generates from its asset base. PHAR trades at a trailing price-to-earnings ratio of 521.43, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.3%, the inverse of the P/E and a quick read on earnings relative to price.

Pharming Group N.V.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.86 places it in the grey zone, a middle ground that warrants monitoring.

Pharming Group N.V. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 74.8% below estimates on average.

Company Profile

Pharming Group N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Leiden, NL. The company is led by CEO Fabrice Chouraqui. PHAR has traded publicly since 2020.

PHAR Financials

PHAR Latest News

PHAR Analyst Consensus

PHAR MoonshotScore

What Investors Ask About Pharming Group N.V. (PHAR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources